{
    "nctId": "NCT06299124",
    "briefTitle": "A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors",
    "officialTitle": "A Phase I Study Evaluating Safety and Tolerability of RGT-419B Monotherapy in Chinese Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer or Other Solid Tumors",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Advanced Solid Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Safety & Tolerability - Number of subjects with Dose-Limiting Toxicities (DLTs) at each cohort dose level",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female \u2265 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Subjects with pathologically confirmed advanced solid tumors who have failed standard-of-care therapy, or have no standard-of-care therapy available, or are currently not eligible for standard-of-care therapy; Subjects with HR+/ HER2- advanced or metastatic breast cancer are preferred.\n* Estimated life expectancy of at least 12 weeks\n\nExclusion Criteria:\n\n* Presence of visceral metastases with severe organ dysfunction\n* Known active hepatitis B or C infection\n* Prior irradiation to \\>25% of the bone marrow and/or inadequate bone marrow function or evidence of clinicallysignificant end-organ damage\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs usedin the study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}